RGD Reference Report - Impact of inflammation on the duodenal mRNA expression of CYP3A and P-glycoprotein in children with Crohn's disease. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Impact of inflammation on the duodenal mRNA expression of CYP3A and P-glycoprotein in children with Crohn's disease.

Authors: Fakhoury, M  Lecordier, J  Medard, Y  Peuchmaur, M  Jacqz-Agrain, E 
Citation: Fakhoury M, etal., Inflamm Bowel Dis. 2006 Aug;12(8):745-9.
RGD ID: 5685614
Pubmed: PMID:16917230   (View Abstract at PubMed)

BACKGROUND AND AIMS: Crohn's disease (CD) is a chronic and invalidating inflammatory bowel disease of unknown etiology. The coordinated action of the cytochrome metabolizing subfamily CYP3A and the transport protein P-glycoprotein (P-gp) in the enterocyte results in a reduced bioavailability of drugs administered orally. Cytokines modulate the expression and functionality of CYP3A and P-gp. Although P-gp results are in disagreement between animal and Caco-2 cell studies, all authors report a decrease in CYP3A levels after exposure to proinflammatory agents. In humans, CYP3A and P-gp mRNA, protein, and functionality levels were higher in various tissues in patients with CD as compared with control groups. Our study's aim was to analyze the impact of systemic inflammation on the expression of CYP3A and P-gp in duodenal normal tissue. MATERIALS AND METHODS: We compared CYP3A and P-gp mRNA expression in 19 noninflamed duodenal biopsies from children with CD with 19 normal biopsies. We used a real-time reverse-transcription-polymerase chain reaction technique. RESULTS: There was a high variability in the expression of the 3 CYP3A isoforms and P-gp. CYP3A4, CYP3A5, and P-gp levels were significantly higher in the CD group than in the control group. DISCUSSION AND CONCLUSIONS: CYP3A and P-gp are involved in the metabolism and transport of many drugs prescribed in CD including corticosteroids. Changes occurring in their duodenal and hepatic expression may explain important interindividual differences in the bioavailability and response to treatment. Further explorations considering protein and activity must be undertaken to understand how such changes affect drug absorption and bioavailability.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
Pediatric Crohn's Disease  IEP 5685614mRNA:increased expression:duodenum:non-inflamed tissueRGD 

Objects Annotated

Genes (Homo sapiens)
CYP3A5  (cytochrome P450 family 3 subfamily A member 5)

Objects referenced in this article
Gene Cyp3a9 cytochrome P450, family 3, subfamily a, polypeptide 9 Rattus norvegicus

Additional Information